JAGX Jaguar Health, Inc.
$2.23▼ -6.12%
Healthcare
Other
Volume 192.5K
Avg Volume (10D) 699.5K
Key Metrics & Fundamentals
Market Cap
$5.17M
P/E Ratio
0.0
Div Yield
0.00%
52W Range
2.00 - 1102.50
% vs 50 MA
-67.98%
% vs 200 MA
-98.16%
RSI-14
41.8
MACD Histogram
+0.0100
Beta (1Y vs SPY)
3.03
Free Cash Flow
-$5.34M
Gross Rev
$1.23M
Gross Profit
$194,000
EBITDA
-$1.63M
COGS
$1.03M
Operating Exp
$7.79M
Operating Income
-$7.60M
EBIT
-$7.60M
Pretax Income
-$12.80M
Net Income
-$12.68M
EPS (Diluted)
-15.70
Price & Volume History
Loading chart…
Recent News
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
ACCESS Newswire · Oct 21, 2026 9:00 AM ET
Top Premarket Decliners
MT Newswires · Oct 16, 2026 7:37 AM ET
Jaguar Health Provides Update Regarding Special Stock Dividend
ACCESS Newswire · Oct 14, 2026 4:15 PM ET
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
ACCESS Newswire · Oct 14, 2026 9:00 AM ET
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
ACCESS Newswire · Oct 13, 2026 9:00 AM ET
Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances
InvestorsHub · Oct 6, 2026 10:53 AM ET
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
ACCESS Newswire · Oct 6, 2026 9:00 AM ET
Jaguar Health Announces a Special Stock Dividend
ACCESS Newswire · Oct 2, 2026 8:35 PM ET
Napo Pharmaceuticals Crofelemer Study Accepted for Presentation at ACG 2026
InvestorsHub · Sep 29, 2026 7:46 AM ET
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
ACCESS Newswire · Sep 29, 2026 4:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See JAGX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.